D. Boral Capital Reiterates “Buy” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $29.00 target price on the stock.

Several other equities analysts also recently issued reports on IMNN. HC Wainwright cut their target price on Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Trading Down 6.5 %

Shares of Imunon stock opened at $0.84 on Tuesday. The firm’s 50 day simple moving average is $0.89 and its two-hundred day simple moving average is $1.10. The firm has a market capitalization of $12.18 million, a price-to-earnings ratio of -0.44 and a beta of 2.12. Imunon has a 12-month low of $0.48 and a 12-month high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.